Where is Indivior headquartered?

Indivior Pty Ltd is recorded with headquarters in Richmond, USA in NovaPharmaNews public regulatory and sponsor datasets.

Is Indivior publicly traded?

Indivior is represented in our database primarily through regulatory marketing authorisation or trial sponsor records; it may not have a US listed ticker in SEC EDGAR.

What drugs are associated with Indivior?

We link 3 drug profile(s) where Indivior appears as originator or marketer in FDA or regional approval metadata.

What clinical trials is Indivior sponsoring?

Indivior is linked to 39 pipeline program(s) sourced from ClinicalTrials.gov and EU CTIS where sponsor names match.

What patents list Indivior as applicant?

34 USPTO PatentsView record(s) name Indivior Pty Ltd or a normalized variant as applicant.

What pipeline phases does Indivior have in our database?

Phase distribution from linked programs: approved: 13, phase 2: 12, phase 1: 6, phase 3: 6.

How many US-approved drugs are linked to Indivior?

2 linked drug profile(s) include US approval status in openFDA-derived metadata.

Does Indivior hold EU marketing authorisations in our data?

1 linked drug(s) include EMA EPAR approval metadata.

Where does NovaPharmaNews source data on Indivior?

Profiles combine SEC EDGAR (US issuers), FDA openFDA, EMA medicines data, ClinicalTrials.gov, EU CTIS, USPTO PatentsView, and regional PBS/PMDA/NMPA feeds. See /about/data-sources.

Is Indivior data investment advice?

No. This profile is compiled from public regulatory records for professional reference only, not investment or medical advice.

Indivior Pty Pharmaceuticals Company Profile

Name: Indivior Pty intelligence dataset
Creator: NovaPharmaNews
License: https://www.sec.gov/edgar.shtml

Company details

Status: Public
HQ: ., Richmond, VA, US
Employees: 967
Programs: 39
Drugs: 19
Patents: 34

Official website ↗ All projects Drug pipeline Patents News & analysis

Quick answer

Indivior is a pharma organization headquartered in Richmond, USA. Primary therapeutic focus areas include Opioid Use Disorder, Opioid Dependence, Schizophrenia, Opioid Dependency, Opiate Dependence. NovaPharmaNews links 39 clinical program(s), 3 drug profile(s), and 34 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources. Pipeline phase mix: approved (13), phase 2 (12), phase 1 (6).

Company snapshot

Indivior is a global pharmaceutical company working to help change patients' lives by developing medicines to treat opioid use disorder (OUD). Our vision is that all patients around the world will have access to evidence-based treatment for OUD and we are dedicated to transforming OUD from a global human crisis to a recognized and treated chronic disease. Building on its global portfolio of OUD tr

3 approved product(s) across US/EU regulatory metadata.
39 active pipeline program(s) linked via ClinicalTrials.gov.
34 US patent(s) indexed to this assignee profile.

Public regulatory, clinical, patent, and corporate records for Indivior Pty. Not investment advice.

Top assets

View drugs (19) View projects (39)

Lead pipeline drugs

alcohol
approved
aspirin
approved
baclofen
approved
buprenorphine
approved

Active clinical programs

Intranasal challenge drug Heroin Dependence
Phase 3
RBP-6000 Opioid Use Disorder
Phase 3
RBP-7000 Schizophrenia
Phase 3
SUBLOCADE Opioid Use Disorder
Phase 3

Momentum

Proprietary activity score for Indivior Pty.

1 active signal

20 /100 +0 vs 30 days ago

Signal breakdown

Clinical trials 46 30d
Nova articles 0 30d
Patents filed 0 30d
FDA actions 0 30d
SEC filings 0 30d
Conference presentations 0 90d
Pipeline advances 0 30d

Competitor landscape

Therapeutic-area overlap peers from registry and pipeline signals.

Peer + 0 momentum

Vertex Pharmaceuticals (Australia)

TA overlap score 40
Peer + 0 momentum

BRIGHT MINDS BIOSCIENCES

TA overlap score 40
Peer + 0 momentum

Jazz Pharmaceuticals Ireland

TA overlap score 40
Peer + 0 momentum

Amneal Pharma Europe

TA overlap score 23

Recent activity

Latest pipeline, patent, and corporate events for Indivior Pty.

Jun 8, 2026 Clinical update
INDV-6000-406 — Approved
Jun 8, 2026 Clinical update
P04843 — Approved
Jun 8, 2026 Clinical update
SUBOXONE sublingual film — Phase 3
Jun 8, 2026 Clinical update
Suboxone Sublingual Film — Approved
Jun 8, 2026 Clinical update
SUBOXONE — Phase 3

View all clinical trial activity →

Quick answers

Common questions about this sponsor — for analysts and search.

What is Indivior Pty?

Indivior is a pharma organization headquartered in Richmond, USA. Primary therapeutic focus areas include Opioid Use Disorder, Opioid Dependence, Schizophrenia, Opioid Dependency, Opiate Dependence. NovaPharmaNews links 39 clinical program(s), 3 drug profile(s), and 34 patent rec
Is Indivior Pty publicly traded?

Indivior Pty appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.
What drugs does Indivior Pty develop or market?

We link 19 drug profile(s) where Indivior Pty is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/indivior-pharmaceuticals#company-drugs.
What are the latest developments for Indivior Pty?

In the last 12 months our linked public records show 39 trial program update(s) and 0 US patent grant(s) tied to this profile.
What therapeutic areas does Indivior Pty focus on?

Indivior Pty focuses on Opioid Use Disorder, Opioid Dependence, Schizophrenia based on our analysis of their pipeline programs and drug development activities.

Therapeutic focus

Therapeutic area distribution

Pipeline concentration by therapeutic area from linked clinical programs.

Programs by therapeutic area

Others

Infectious Disease

Neurology